Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US

Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.

Alzheimer's DiseaseBy alessandroJuly 16, 2011Leave a comment

Alzheimer’s Association International Conference, July 16-21, 2011, Paris, France Tangui Maurice, Vanessa Villard, Johann Meunier, Valentine Lahmy, Emeline Keller and Alexandre Vamvakides View Poster

The novel tetrahydrofuran derivative ANAVEX2-73 attenuated GSK-3β activation and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model in mice.

Anavex2-73By alessandroJuly 16, 2011Leave a comment

Alzheimer’s Association International Conference, July 16-21, 2011, Paris, France Valentine Lahmy, Susanna Malmstrom, Johann Meunier, Vanessa Villard, Alexandre Vamvakides and Tangui Maurice View Poster

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top